// App-Quantinova.ai

: ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Researchers

Presenter

  • Timothy Hughes

Principal Investigators

  • Jorge E. Cortes

  • Naoto Takahashi

  • Richard A. Larson

  • Ghayas C. Issa

  • Felice Bombaci

  • Nicholas Ramscar

  • Shruti Kapoor

  • Sophie Ifrah

  • Andreas Hochhaus

Medical Centers

  • Novartis Pharma AG, Basel, SWITZERLAND

  • Gruppo AIL Pazienti Leucemia Mieloide Cronica, Rome, Italy

  • Section of Hematology/Oncology, University of Chicago, Chicago, IL

  • SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia

  • Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan

  • Novartis Pharma AG, Paris, France

  • Department of Leukemia, Universit Y of Texas At Houston, Houston, TX

  • Univerisitätsklinikum Jena, Jena, Germany

  • Georgia Cancer Center Augusta University, Augusta, GA

Locations

  • United States

  • Switzerland

  • Germany

  • France

  • Australia

  • Italy

  • Japan

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Chronic Myelogenous Leukemia

  • Renal insufficiency

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

  • Ischemia Modified Albumin

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

  • Anagrelide hydrochloride

  • ABL001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved